The Natural History of the Systemic Inflammatory Response Syndrome (SIRS): A Prospective Study

JAMA: The Journal of the American Medical Association

Volumn 273, Issue 2, 1995, Pages 117-123

  Rangel Frausto, M Sigfrido ^a   Pittet, Didier ^a   Costigan, Michele ^a   Hwang, Taekyu ^a   Davis, Charles S ^a   Wenzel, Richard P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DOPAMINE; HYPERTENSIVE AGENT;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK;

DIAGNOSIS-RELATED GROUPS; FEVER; HOSPITALS; HUMAN; HYPOTHERMIA; LEUKOCYTE COUNT; MULTIPLE ORGAN FAILURE; PREVALENCE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SEPSIS; SEPSIS SYNDROME; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TACHYCARDIA;

EID: 0028893025     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1995.03520260039030     Document Type: Article

References (29)

1. Parker MM, Parrillo JE. Septic shock: hemodynamics and pathogenesis. JAMA. 1983;250:3324-3327.
2. Wenzel RP. Anti-endotoxin monoclonal antibodies: a second look. N Engl J Med. 1992;326:1151-1153.
3. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
4. Niederman MS, Fein AM. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence. Clin Chest Med. 1990;11:633-656.
5. Centers for Disease Control and Prevention, National Center for Health Statistics. Mortality Patterns—United States, 1990. Monthly Vital Stat Rep. 1993;41:5.
6. Bone RC. Sepsis syndrome: new insights into its pathogenesis and treatment. Infect Dis Clin North Am. 1991;5:793-805.
7. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Crit Care Med. 1989;17:389-393.
8. Bone RC. Sepsis, the sepsis syndrome, multiorgan failure: a plea for comparable definitions. Ann Intern Med. 1991;114:332-333.
9. American College of Chest Physicians—Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-875.
10. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471-1477.
11. Nathan CF. Secretory macrophages. J Clin Invest. 1987;79:319-326.
12. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225-1230.
13. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429-436.
14. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
15. Exley AR, Cohen J, Buurman W, et al. Monoclonal antibody to TNF in severe septic shock. Lancet. 1990;335:1275-1277.
16. Wherry J, Wenzel R, Wunderink R, et al. Monoclonal antibody to human necrosis factor (TNF Mab): multi-center efficacy and safety study in patients with the sepsis syndrome. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans, La. Abstract 696:246.
17. Opal SM, Fisher CJ, Slotman GJ, et al. The phase II interleukin-1 receptor antagonist (IL-1ra) sepsis syndrome trial: analysis of clinical, cytokine, and microbial features with outcome. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11-14, 1992; Anaheim, Calif. Abstract 1570:372.
18. Pittet D, Rangel-Frausto MS, Tarara D, Costigan M, Wenzel RP. SIRS, sepsis, and severe sepsis: incidence, morbidities, and outcomes in SICU patients. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans, La. Abstract 1301:358.
19. Broderick A, Mori M, Nettleman M, Streed S, Wenzel RP. Nosocomial infections: validation of surveillance and computer modeling to identify patients at risk. Am J Epidemiol. 1990;131:734-742.
20. Pittet D, Omahen J, Tarara D, Wenzel RP. Current risk factors for nosocomial bloodstream infection in a tertiary health care center. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago, Ill. Abstract 800:232.
21. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720-723.
22. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;2:81-84.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
24. McCabe WR, Jackson GG. Gram-negative bacteremia, II: clinical, laboratory, and therapeutic observations. Arch Intern Med. 1962;110:856-864.
25. Owens WD, Felts JA, Spitznagel EL Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology. 1978;49:239-243.
26. Woolson R. Statistical Methods for the Analysis of Biomedical Data. New York, NY: John Wiley & Sons Inc; 1987:252-260.
27. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980:10-20.
28. SAS Institute. SAS/STAT User's Guide: Version 6.4th ed. Vol 2. Cary, NC: SAS Institute; 1990.
29. Freeman J, Hutchinson GB. Prevalence, incidence, and duration. Am J Epidemiol. 1980;112: 707-723.